GMPLEX™ Growth Pathways close Australia’s manufacturing middle with a modular, multi-tenant platform: begin by manufacturing through us, graduate into your own independently controlled module, and keep tapping the shared backbone long after you have your own space.
Document version 1.0 · last updated 1 Aug 2026
The brochure covers all five stages and the shared backbone capabilities in a 3-page PDF.
Regulatory disclaimer: This brochure is for general information only and does not constitute regulatory, legal, GMP certification, or TGA approval advice. Specific compliance requirements should be confirmed with GMPLEX™ and the relevant regulatory authorities.
Local research and clinical trials are strong, but most medicines and diagnostic inputs are imported. GMPLEX™ Growth Pathways keep more of that value in Australia by helping products move from CDMO to dedicated GMP manufacturing.
>90%
of prescription medicines are imported into Australia
97%
of diagnostic raw materials and components are imported
2,046
clinical trials delivered by AAMRI member institutes in 2023
$5.80
returned per $1 invested in Australian clinical trials
Sources: NHMRC Draft National Health and Medical Research Strategy (2026); AAMRI 2024 Report; AAMRI / Nous Group, Australia's Medical Research Advantage (2026).
The GMPLEX™ Growth Pathway lets you start lean, scale confidently, and graduate into your own space without ever losing the support of the GMPLEX™ campus.
Launch production through GMPLEX™ as your contract development and manufacturing partner — no capex, no facility build, no qualification programme of your own.
Ideal for early-stage companies, first-in-human products and market entrants that need GMP supply without the capital burden of a dedicated facility. We manage the validation, quality system and regulatory interface while you retain your IP and product strategy.
Move into a right-sized GMP module configured, qualified and operationalised around your process and regulatory pathway.
A dedicated module is designed to your process requirements — cleanroom grade, HVAC, utilities, environmental monitoring and documentation — all qualified under the GMPLEX™ quality system and ready for your batches.
Run controlled manufacturing in an independently serviced module with its own airlocks, HVAC, EMS, BMS and utilities. Your process, your IP, your quality system.
Operate with operational independence while remaining part of the GMPLEX™ campus. Your team controls batch release, deviations and change control, supported by shared utilities, calibration and campus-wide compliance.
Add adjacent modules, services and capacity as clinical and commercial demand increases — without disrupting neighbouring tenants.
Scale horizontally with additional modules, packaging lines, stability storage or analytical support. Expansion is modular and fast because the infrastructure backbone is already qualified and live.
Progress to your own dedicated footprint while staying plugged into the GMPLEX™ backbone — backup manufacturing house, warehousing and cold rooms remain available.
Graduate from tenancy to ownership on the same campus. Even with your own building, you retain access to backup manufacturing, warehousing, cold rooms and the technical ecosystem, so scale never outruns support.
The compliant infrastructure is built once and shared. Tenants keep full operational independence, and even after moving into their own space they retain access to the campus backup house, warehousing and cold rooms.
Retain surge and contingency capacity through GMPLEX™ modules and our CDMO network, so a single line outage never stops supply.
GMP-compliant storage, picking and Australia-wide distribution scaled to your batch volumes, without leasing your own warehouse.
Monitored 2–8 °C and controlled-temperature cold rooms with continuous EMS logging for cold-chain products and reference retains.
Purified water, clean utilities, waste, calibration and servicing maintained once across the campus and shared by every tenant.
Design, validation, engineering, quality and regulatory specialists already qualified on the campus and available on demand.
Shared compliance backbone lowers capex and opex while GMP separation is preserved where operations require it.
A clear, staged onboarding so you know exactly what happens between first conversation and first compliant batch.
We map your product, volumes and timeline against the available GMP modules, CDMO capacity and shared services.
You receive a costed pathway proposal with module allocation, quality responsibilities and a staged commercial model.
Quality agreements, documentation and tech transfer run in parallel with module fit-out and equipment qualification.
Validation activities complete, release processes go live, and your first batch is manufactured under the GMPLEX™ quality system.
Answers to the most common questions about moving from CDMO to your own module, using the shared backbone, and getting started.
GMPLEX™ CDMO, where we manufacture on your behalf under our licence and quality system; GMPLEX™ Managed Manufacturing, where you own the product and process while we provide the people, systems and oversight; and GMPLEX™ Dedicated GMP Modules, where you operate your own qualified module on campus. Start where you need and scale when you are ready.
The backup house is surge and contingency manufacturing capacity retained on the GMPLEX™ campus. Use it when your own line is down, demand spikes, or you need a second-source batch without qualifying a new contract manufacturer. Access is reserved for pathway partners and tenants on agreed terms, and it remains available after you move into your own GMP space.
Most partners start with GMPLEX™ warehousing and distribution: GMP-compliant ambient storage, quarantine, release, picking and Australia-wide distribution. You only take on your own warehouse when your volume makes it economical, and you can keep using GMPLEX™ warehousing as backup or overflow after you do.
Validated cold rooms (2–8 °C and controlled-temperature options) are part of the shared backbone. Tenants and owned-space partners book space by pallet or shelf with continuous environmental monitoring and alarm escalation, so you do not need to build and qualify your own cold-chain storage early on.
Most partners reach commercial supply through our CDMO service within 12–18 months of signing, depending on technology transfer and validation. Moving into your own dedicated module usually follows once the process is stable and demand predictable, often in the 24–36 month range, and the timeline flexes either way.
No. Because the quality system, utilities and campus infrastructure stay consistent, moving from CDMO to module to owned space is treated as a controlled change within the same GMPLEX™ ecosystem rather than a site transfer. Filings and supply continuity are managed through the same quality unit and change-control process.
Yes. Scale never outruns support. Even after you graduate to your own building you retain access to the backup manufacturing house, warehousing, cold rooms, shared utilities and the campus technical ecosystem on commercial terms.
The campus is built for oral solid dose and related non-sterile forms, with capability from pilot and scale-up batches through to commercial production runs, plus packaging and serialisation-ready finishing. Talk to us about your dosage form and volumes and we will map them to the right pathway.
Send an enquiry through the contact form with your product type, target volumes and timing. A short technical call follows, then we issue an indicative pathway and pricing outline. To move to proposal we typically need your process description, specifications, bill of materials and any existing regulatory dossier under confidentiality.
Share a few details about your stage and goals and we will shape a Growth Pathway plan that fits your timeline and budget.
Tell us where you are on the pathway and where you want to go. A member of the GMPLEX™ team will respond within two business days.
Ready to grow with GMPLEX™?
Request a consultation and start your Growth Pathway plan.
Document version 1.0 · last updated 1 Aug 2026
